World's Best Scientists 2026 revealed!
Masakazu Toi

Masakazu Toi

D-Index & Metrics

Medicine

D-Index
99
Citations
48085
World Ranking
8449
National Ranking
218

Masakazu Toi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Masakazu Toi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 933 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Masakazu Toi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Masakazu Toi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Masakazu Toi is affiliated with Kyoto University in Japan and has a substantial body of work focused primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research predominantly addresses oncology, with specific concentration on breast cancer and related treatment methodologies.

The scientist's research topics encompass various areas including:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer-related Molecular Pathways
  • Breast Lesions and Carcinomas
  • Lung Cancer Research Studies

Masakazu Toi frequently publishes in several well-recognized venues, notably:

  • Cancer Research
  • Annals of Oncology
  • Breast Cancer
  • Journal of Clinical Oncology
  • Breast Cancer Research and Treatment

Their most recent published papers include:

  • "Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021," 2021, Annals of Oncology
  • "Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up," 2023, Annals of Oncology
  • "Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer," 2023, New England Journal of Medicine
  • "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial," 2022, The Lancet Oncology
  • "Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer," 2022, Annals of Oncology

Collaboration is a notable feature of Masakazu Toi's research, working extensively with co-authors such as:

  • Norikazu Masuda
  • Satoshi Morita
  • Masahiro Takada
  • Shinji Ohno
  • Kosuke Kawaguchi

The combination of these collaborations and frequent publications in leading oncology journals reflects a focused career centered on cancer research, particularly breast cancer treatment and its molecular aspects. Their work contributes to clinical and pharmacological understanding through a multidisciplinary approach integrating genetics, molecular biology, and therapeutic strategies.

Best Publications

  • Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    A Goldhirsch;E P Winer;A S Coates;R D Gelber

  • Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

    Norikazu Masuda;Soo-Jung Lee;Shoichiro Ohtani;Young-Hyuck Im

  • MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

    Matthew P. Goetz;Masakazu Toi;Mario Campone;Joohyuk Sohn

  • MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

  • Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

    Chikashi Nakanishi;Masakazu Toi

  • Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.

    Takayuki Ueno;Masakazu Toi;Hisashi Saji;Mariko Muta

  • Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation

    P. E. Vermeulen;G. Gasparini;S. B. Fox;Masakazu Toi

  • The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

    H J Burstein;G Curigliano;B Thürlimann;W P Weber

  • Association of Vascular Endothelial Growth Factor Expression with Tumor Angiogenesis and with Early Relapse in Primary Breast Cancer

    Masakazu Toi;Seigo Hoshina;Toshiaki Takayanagi;Takeshi Tominaga

  • Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

    Fabrice André;Ruth O'Regan;Mustafa Ozguroglu;Masakazu Toi

  • Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression

    Masakazu Toi;Kazuo Inada;Hideo Suzuki;Takeshi Tominaga

  • Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial

    David Cameron;Julia Brown;Rebecca Dent;Christian Jackisch

  • MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.

    Stephen Johnston;Miguel Martin;Angelo Di Leo;Seock Ah Im

  • Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma.

    Masakazu Toi;Takeshi Tominaga;Jitsuo Kashitani

  • Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Edith A. Perez;Carlos Barrios;Wolfgang Eiermann;Masakazu Toi

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

  • Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma

    Hisashi Saji;Morio Koike M.D.;Takao Yamori;Shigehira Saji M.D.

  • Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308))

    G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant

Frequent Co-Authors

Hiroji Iwata
Hiroji Iwata Aichi Cancer Center
Satoshi Morita
Satoshi Morita Kyoto University
Kaori Togashi
Kaori Togashi Kyoto University
Hironobu Sasano
Hironobu Sasano Tohoku University
Hiroshi Ishiguro
Hiroshi Ishiguro Osaka University
George W. Sledge
George W. Sledge Stanford University
Naoki Yamamoto
Naoki Yamamoto Kyoto University
Yasuo Ohashi
Yasuo Ohashi Chuo University
Fabrice Andre
Fabrice Andre Institut Gustave Roussy
Yoshimasa Tanaka
Yoshimasa Tanaka Nagasaki University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering studying Medicine in the USA, you may also be interested in allied online programs that offer flexible pathways into healthcare careers. Pursuing a health administration degree is a smart option for those who want to lead within hospitals or medical facilities without becoming a physician.

For those ready to move into advanced healthcare leadership roles, there are cheapest online mha programs that balance affordability with graduate-level expertise. Nurses aiming to reach top clinical positions might consider the best online bsn to dnp programs, allowing career advancement while continuing to work.

If pharmacy fascinates you, enrolling in a pharmacy school online accredited program is now more accessible than ever, combining rigorous academic standards with distance learning convenience.

These degree options enable you to join the healthcare sector through diverse routes, with online flexibility to meet your needs and career goals. Consider them as alternative or complementary pathways alongside medical school.

Best Scientists Citing Masakazu Toi

Trending Scientists

Recently Published Articles